| Literature DB >> 32231424 |
Wang-Shu Zhu1, Si-Ya Shi1, Ze-Hong Yang1, Chao Song1, Jun Shen1.
Abstract
BACKGROUND: Postoperative liver failure is the most severe complication in cirrhotic patients with hepatocellular carcinoma (HCC) after major hepatectomy. Current available clinical indexes predicting postoperative residual liver function are not sufficiently accurate. AIM: To determine a radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting liver failure in cirrhotic patients with HCC after major hepatectomy.Entities:
Keywords: Gadoxetic acid; Hepatocellular carcinoma; Liver failure; Magnetic resonance imaging; Radiomics
Mesh:
Substances:
Year: 2020 PMID: 32231424 PMCID: PMC7093309 DOI: 10.3748/wjg.v26.i11.1208
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Flow diagram shows patient selection. LF: Liver failure; MRI: Magnetic resonance imaging.
Figure 2Workflow of necessary steps in current study. Region of interests were drawn on hepatobiliary phase gadoxetic acid-enhanced magnetic resonance images. For feature selection, the least absolute shrink-age and selection operator method was applied to select significant features. The radiomics signature was constructed by a linear combination of selected features. The performance of the prediction model was assessed by the area under a receiver operating characteristic curve and the calibration curve. To provide a more understandable outcome measure, a nomogram was built for individualized evaluation, followed by decision curve analysis. ROIs: Region of interests.
Categories of the quantitative radiomics features obtained for analysis
| First-order and distribution statistics, | Minimum intensity, Maximum intensity, Mean intensity, Median intensity, Standard deviation, Variance, Volume count, Voxel value sum, Range mean deviation, Relative deviation, Skewness, Kurtosis, Uniformity, Energy, Entropy, Frequency size, Quantile 5, Quantile 10, Quantile 25, Quantile 50, Quantile 75, Quantile 90, Quantile 95 |
| Gray-level co-occurrence matrix, | Glcm bin size, Glcm total frequency, Glcm matrix mean, Glcm relative Frequency, Energy, Entropy, Inertia, Correlation, Inverse difference moment, Cluster shade, Cluster prominence, Haralick correlation, Haralick entropy, Angular second moment, Contrast, Haralick variance, sum Average, sum Variance, sum Entropy, Difference variance, Difference entropy, Inverse difference moment normalized, Minimum intensity, Maximum intensity, Number of intensity bins, Minimum size, Maximum size, Number of size bins |
| Gray-level run length matrix, | Short run emphasis (SRE), Long run emphasis (LRE), Gray level non-uniformity (GLN), Run length non-uniformity (RLN), Low gray level run emphasis (LGLRE), High gray level run emphasis (HGLRE), Short run low gray level emphasis (SRLGLE), Short run high gray level emphasis (SRHGLE), Long run low gray level emphasis (LRLGLE), Long run high gray level emphasis (LRHGLE) |
Clinicopathological characteristics of 101 hepatitis B virus-related cirrhotic patients with hepatocellular carcinoma
| Sex | 0.439 | ||
| Male | 9 (90) | 50 (89) | |
| Female | 1 (10) | 6 (12) | |
| Age in yr | 55 (22-78) | 55 (40-67) | 0.958 |
| Primary tumor | |||
| Tumor size in mm | 59 (15-154) | 38 (10-197) | 0.069 |
| Single, | 4 (27) | 60 (70) | |
| Multiple in | 11 (73) | 26 (30) | |
| Baseline serological index | |||
| Aspartate aminotransferase in IU/L | 59 (17-116) | 33 (17-1663) | 0.030 |
| Alanine aminotransferase in IU/L | 34 (17-98) | 31 (11-1491) | 0.248 |
| Total bilirubin in mg/dL | 18.2 (8.2-37.9) | 15.7 (3.2-35.5) | 0.314 |
| Albumin in g/L | 38.7 (30.9-45.8) | 40.3 (23.0-50.3) | 0.135 |
| Alkaline phosphatase in U/L | 131 (71-365) | 91 (41-410) | 0.004 |
| Platelet as /L | 200 (111-496) | 188 (49-489) | 0.462 |
| Prothrombin time in s | 12.8 (11.3-14.9) | 12.3 (10.6-16.8) | 0.138 |
| Cholinesterase in U/L | 6271 (2522-8417) | 6714 (2334-12360) | 0.110 |
| ICG test | |||
| Elimination rate constant in K as min-1 | 0.13 (0.09-0.19) | 0.21 (0.12-0.29) | 0.308 |
| Retention rate at 15 min as R15 in % | 8.2 (1.3-28.4) | 12.8 (6.1-18.0) | 0.002 |
| The half-life as T1/2 in min | 6.36 (3.73-7.88) | 3.27 (2.39-5.68) | 0.061 |
| Baseline score | |||
| Child-Pugh classification | 0.786 | ||
| A | 15 (100) | 81 (94) | |
| B | 0 (0) | 5 (6) | |
| C | 0 (0) | 0 (0) | |
| Fibrosis grade on specimen | 0.174 | ||
| F1 | 1 (7) | 9 (11) | |
| F2 | 0 (0) | 8 (9) | |
| F3 | 0 (0) | 7 (8) | |
| F4 | 9 (60) | 14 (16) | |
| N/A | 5 (33) | 48 (56) |
Data are numbers of patients, with percentages in parentheses, except otherwise indicated.
Numbers in parentheses are ranges;
If the number of lesions is greater than 2, the largest lesion was chosen to measure the maximal dimension. N/A: Not available.
Figure 3Radiomic feature selection using least absolute shrink-age and selection operator logistic regression. A: Selection of tuning parameters (l) in the least absolute shrink-age and selection operator model used 10-fold cross-validation via minimum criteria. The area under the curve was plotted vs log (λ). Dotted vertical lines were drawn at the optimal values using the minimum criteria and the 1 standard error of the minimum criteria (the 1 - standard error criteria); B: Least absolute shrink-age and selection operator coefficient profiles of the radiomic features. A vertical line was plotted at the optimal λ value, which resulted in five features with nonzero coefficients.
Figure 4Radiomics nomogram and receiver operating characteristic curves and calibration curves of three predictive models. A: A nomogram was developed with incorporation of radiomics signature and indocyanine green retention rate at 15 min; B: Comparison of receiver operating characteristic curves of clinical prediction model, radiomics signature and radiomics-based model for the prediction of liver failure; C: Calibration curves of the nomogram.
Receiver operating characteristics analysis of the predictive value of clinical prediction model, radiomics signature and radiomics-based model
| AUC (95%CI) | 0.810 (0.691-0.929) | 0.809 (0.713-0.906) | 0.894 (0.823-0.964) |
| Optimized Youden Index | 0.579 | 0.556 | 0.712 |
| Sensitivity (95%CI) | 0.800 (0.514-0.947) | 0.800 (0.514-0.947) | 0.933 (0.660-0.997) |
| Specificity (95%CI) | 0.779 (0.674-0.858) | 0.756 (0.649-0.839) | 0.779 (0.674-0.859) |
| PPV (95%CI) | 0.387 (0.224-0.577) | 0.364 (0.210-0.549) | 0.424 (0.260-0.606) |
| NPV (95%CI) | 0.957 (0.872-0.989) | 0.956 (0.868-0.989) | 0.985 (0.910-0.999) |
| Accuracy (95%CI) | 0.782 (0.691-0.852) | 0.762 (0.670-0.835) | 0.802 (0.713-0.869) |
AUC: Area under the curve; CI: Confidence interval; NPV: Negative predictive value; PPV: Positive predictive value.
Figure 5Decision curve analysis for each model. The y-axis measures the net benefit, which is calculated by summing the benefits (true-positive findings) and subtracting the harms (false-positive findings), weighting the latter by a factor related to the relative harm of undetected liver failure compared with the harm of unnecessary treatment. The decision curve showed the application of radiomics-based model to predict liver failure adds more benefit than treating all or none of the patients, clinical prediction model, and radiomics signature.